Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

SATOR Therapeutics LLC

  • Stephen Charles, SATOR Therapeutics LLC

THE SATOR PLATFORM for the Comprehensive Treatment of Metastatic Cancers:

PLATFORM concept of PANELS of nonengineered, nonpathogenic SATOR viruses proven in a variety of human cancers in cell culture, mouse xenograft models, and via human compassionate use studies.

Pretreatment testing with efficacy–predicting COMPANION DIAGNOSTICS minimizes treatment of non–responders.

No serious adverse events reported; substantial life extension achieved.

Efficient US regulatory pathway due to choice of orphan indication ovarian cancer.

Comprehensive worldwide patent protection applied for.

Upcoming Milestones:

Complete $40 million Series A private financing.

INTERACT meeting with FDA.

Orphan drug designation submission to US FDA and European EMA.

cGMP manufacturing and preclinical testing of 3 lead candidate SATOR viruses; development and validation of 3 efficacy–predicting companion diagnostics.

IND preparation and filing for 3 SATOR viruses.

Conduct Phase 1b patient study in ovarian cancer.

  • Date:Tuesday, February 12
  • Time:2:00 PM - 2:15 PM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23566
  • Goal for Presentation:Investment
  • Company Website:Under construction
  • Company HQ City:Cleveland
  • Company HQ State:Ohio
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$400,000
  • Size of Last Investment Round:$400,000 ongoing
  • Previous and Current Investors:Angels/high net worth individuals
  • CEO/Top Company Official:SATOR Therapeutics LLC
  • Year Founded:2018
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:Panel of 3 SATOR viruses for metastatic ovarian cancer
  • Development Phase of Primary Product:Pre-Clinical
Speakers
Stephen Charles
SATOR Therapeutics LLC
Back